Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | — | — | — | 16.18 | — | — | 0.07 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | 12.44 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.00 | 0.21 | 0.00 | 0.00 | 0.45 | 0.48 | 0.53 | 0.19 | 1.27 | 0.65 | 0.43 | 0.61 | 0.66 |
| — | -56.9% | -99.9% | -99.3% | -64.7% | -26.3% | +21.7% | -68.7% | +93.9% | +21.6% | -31.6% | -34.0% | -39.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 0.41 | — | — | 0.05 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 50.0% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | -6156.7% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | 3074.4% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -82.0% | -843.9% | -124.2% | -39.9% | 38.4% | -69.6% | -127.1% | 108.6% | -94.8% | -46.4% | -70.9% | -48.2% | -70.7% |
| — | -1113.1% | +2.3% | -136.7% | +140.5% | -50.0% | -79.4% | +325.2% | -34.1% | -145.2% | -11.5% | -133.3% | -148.8% | |
| ROA | -18.2% | -121.1% | -36.3% | -14.8% | 9.5% | -9.3% | -40.9% | 32.7% | -15.1% | -11.5% | -17.4% | -11.2% | -22.5% |
| — | -1202.5% | +11.2% | -145.3% | +163.0% | +19.5% | -134.7% | +390.8% | +33.2% | -66.6% | +39.5% | -0.7% | -37.5% | |
| ROIC | -144.7% | — | -23.0% | -29.6% | -58.7% | -77.4% | -88.4% | -21.8% | -22.4% | -35.3% | -138.3% | -58.1% | -90.7% |
| — | — | +73.9% | -35.5% | -161.8% | -119.0% | +36.1% | +62.4% | +75.3% | -18.0% | -74.2% | -104.8% | -112.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 20.8% YoY to 0.33x, strengthening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 374.89 | 1.27 | 0.15 | 0.18 | 0.46 | 0.97 | 0.10 | 4.96 | 2.29 | 0.22 | 0.27 | 0.23 |
| — | +82010.6% | +31.3% | +59.5% | -96.3% | -80.1% | +349.3% | -64.4% | +2079.4% | +1338.1% | +11.3% | +288.8% | +229.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.45 | 0.33 | 0.43 | 0.25 | 0.45 | 0.27 | 0.23 | 0.67 | 1.35 | 2.40 | 3.51 | 1.89 | 3.00 |
| — | +20.8% | +83.9% | -63.3% | -66.6% | -88.7% | -93.3% | -64.6% | -55.2% | -5.4% | +42.3% | -45.4% | -37.1% | |
| Quick Ratio | 0.45 | 0.33 | 0.43 | 0.25 | 0.45 | 0.27 | 0.23 | 0.67 | 1.35 | 2.40 | 3.51 | 1.89 | 3.00 |
| — | +20.8% | +83.9% | -63.3% | -66.6% | -88.7% | -93.3% | -64.6% | -55.2% | -5.4% | +42.3% | -45.4% | -37.1% | |
| Interest Coverage | -106.46 | — | -50.43 | -204.50 | -90.84 | -92.96 | -104.11 | -338.85 | -413.25 | -360.77 | -519.77 | -349.25 | -831.69 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonWindtree Therapeutics, Inc.'s current P/E is -0.0x. The average P/E over the last 1 quarters is 16.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Windtree Therapeutics, Inc.'s business trajectory between earnings reports.